Neostigmin Panpharma (Neostigmine Methylsulfate)

Neostigmine inhibits acetylcholinesterase, the enzyme that breaks down acetylcholine. By blocking this enzyme, it raises acetylcholine levels at neuromuscular junctions and autonomic ganglia, improving signal transmission and promoting muscle contraction.

The appropriate dose of Neostigmin Panpharma is determined by the prescribing clinician based on the specific indication, patient weight, renal function, and clinical response. Dosage regimens are individualized and should follow local prescribing guidelines.

Safety data for neostigmine in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Use only if the potential benefit justifies any potential risk to the fetus or infant, and consult a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Neostigmine is a reversible acetylcholinesterase inhibitor, whereas alternative agents such as sugammadex directly encapsulate certain neuromuscular blockers. Neostigmine is less expensive and widely available but may cause cholinergic side effects, requiring concomitant antimuscarinic therapy in some cases.

Neostigmin Panpharma should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and extreme temperature fluctuations to maintain stability.

The drug is supplied as a sterile injectable solution and can be given intramuscularly, intravenously, or subcutaneously. Administration technique follows standard aseptic practices, and the route is selected according to the clinical situation and prescriber’s judgment.

Serious risks include bradycardia, bronchospasm, and cholinergic crisis, which can lead to severe muscle weakness, respiratory failure, or cardiac complications. Prompt recognition and supportive measures, such as atropine for bradycardia, are essential.

Neostigmin Panpharma is contraindicated in patients with known hypersensitivity to neostigmine or any formulation components, mechanical intestinal obstruction, or severe bronchial asthma. Caution is also advised in individuals with cardiac conduction disorders or renal failure.